AFC
BIO icon

Ares Financial Consulting’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ares Financial Consulting’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47K Hold
5
– – ﹤0.01% 950
2026
Q1 		$1.39K Hold
5
– – ﹤0.01% 903
2025
Q4 		$1.51K Buy
+5
New +$1.56K ﹤0.01% 706

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
HP
Hosking Partners London, United Kingdom $3.01B AUM 83.99% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
AL
Arnhold LLC New York $1.43B AUM 59.3% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Ares Financial Consulting's BIO Position: Q2 2026 in Review

Ares Financial Consulting held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 5 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #950.

Ares Financial Consulting first reported a position in BIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.51K in Q4 2025. 153 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Ares Financial Consulting held 5 shares of Bio-Rad Laboratories Class A worth $1.47K as of Q2 2026.
  • Ares Financial Consulting left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #950 holding.
  • Ares Financial Consulting first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and has held it in 3 quarters since.
  • Ares Financial Consulting's Bio-Rad Laboratories Class A position peaked at $1.51K in Q4 2025.
  • 153 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.